SB 9200 an oral selective immunomodulator is safe and efficacious in treatment-naive, non-cirrhotic HBV patients: Results from Cohort 1 of the ACHIEVE trial
Refereed conference paper presented and published in conference proceedings

Full Text

Times Cited
Web of Science2WOS source URL (as at 13/10/2021) Click here for the latest count

Other information
All Author(s) ListYuen MF, Coffin CS, Elkhashab M, Greenbloom S, Ramji A, Chan HLY, Iyer RP, Locarnini S, Macfarlane C, Afdhal NH, Kim W
Name of ConferenceThe Liver Meeting of the American Association for the Study of Liver Diseases
Start Date of Conference20/10/2017
End Date of Conference24/10/2017
Place of ConferenceWashington DC
Country/Region of ConferenceUnited States of America
Proceedings TitleHepatology
Title of PublicationHEPATOLOGY
Volume Number66
Issue NumberSuppl. 1
Pages22A - 22A
LanguagesEnglish-United Kingdom
Web of Science Subject CategoriesGastroenterology & Hepatology;Gastroenterology & Hepatology

Last updated on 2021-14-10 at 00:40